Chimeric antigen receptor T-cells targeting the CD19 antigen have achieved impressive results in patients with relapsed/refractory (R/R) B-cell malignancies. leading to their approval in the European Union and other jurisdictions. In Spain. the 100% academic anti-CD19 CART-cell product varnimcabtagene autoleucel (var-cel. https://www.ceomelinh.com/product-category/kentucky/